For example, it has been shown that myeloma cells decrease OPG availability by internalizing it through binding to glycosaminoglycan side chains of surface syndecan-1 and degradation to lysosomes, thereby regulating its inhibitory effect on RANKL [116]. This evidence concerns the gene SDC1 and plasma cell myeloma.